Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings GlaxoSmithKline Pharmaceuticals Limited: Strengths and Weaknesses

Highlights: GlaxoSmithKline Pharmaceuticals Limited
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: GlaxoSmithKline Pharmaceuticals Limited
  • With an expected P/E ratio at 42.08 and 36.55 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company appears highly valued given the size of its balance sheet.
  • The company is not the most generous with respect to shareholders' compensation.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
4.78B - - - -
1,055B
A
632B -
BBB
- -
442B
AA
-
351B
AA
290B
AAA
243B
A
227B
A
200B
A
172B
AA
Average 361.73B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. GLAXO Stock
  4. GLAXO Stock
  5. Ratings GlaxoSmithKline Pharmaceuticals Limited